Daniel Nowak

Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal

Marc Hinderer, Melanie Boerries, Martin Boeker, 2020, Diagnostics.

Cost synergies in MaA

Daniel Nowak, Robert Nyman, 2007 .

In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.

Daniel Nowak, P. Atadja, D. Nowak, 2004, Biochemical pharmacology.

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms

Masao Nagasaki, Satoru Miyano, Yuichi Shiraishi, 2012, Nature Genetics.

Differentiation therapy of leukemia: 3 decades of development.

Daniel Nowak, H Phillip Koeffler, D. Nowak, 2009, Blood.